What 10 Analyst Ratings Have To Say About R1 RCM
Portfolio Pulse from Benzinga Insights
R1 RCM (NASDAQ:RCM) has been analyzed by 10 analysts, showing a mix of bullish and bearish sentiments. The average 12-month price target is now $17.05, down from $19.70, with a high estimate of $20.00 and a low of $11.00. Analysts from firms like Barclays, Morgan Stanley, JP Morgan, RBC Capital, Canaccord Genuity, Cantor Fitzgerald, Keybanc, and Truist Securities have provided various ratings and price target adjustments. R1 RCM offers technology-driven solutions for healthcare providers and has shown a revenue growth of 15.6% as of September 30, 2023. However, its ROE and ROA are below industry averages, while its net margin is above average, and it has a sound debt-to-equity ratio.
January 03, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
R1 RCM has a mixed outlook from analysts, with a downward revision in the average price target to $17.05, indicating potential pressure on the stock price in the short term.
The reduction in the average price target by analysts suggests that there may be concerns about the company's future performance, which could lead to a decrease in the stock price in the short term. The strong revenue growth is a positive sign, but the below-average ROE and ROA may raise questions about the company's efficiency and profitability, potentially affecting investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100